Cushing Syndrome
A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.
Drugs by status
Approved for this indication (10)
Phase 4 trials (1)
Phase 3 trials (2)
Phase 2 trials (18)
Phase 1 trials (2)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (12)
- AstraZeneca
- Millendo Therapeutics, Inc.
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Roma La Sapienza
- Azienda Ospedaliera San Camillo Forlanini
- Cedars-Sinai Medical Center
- Medical College of Wisconsin
- University of Milan
- University of Turin
- University of Oxford
- University of Brescia
Organization Involved with Other Experimental Indications (1)